Our people
What we do
Industries Practices Legal Tech

Aerospace and Defense

Automotive and Mobility

Consumer

Education

Energy and Natural Resources

Financial Institutions

Insurance

Life Sciences and Health Care

Manufacturing and Industrials

Mobility and Transportation

Private Capital

Real Estate

Sports, Media and Entertainment

Technology and Telecoms

Transportation and Logistics

Corporate & Finance

Disputes

Intellectual Property, Media, and Technology

Regulatory
Case studies
Our thinking
ESG
Join us

Search

Search

Deutsch
English
Español
Français
中文
日本語

About us
Where we are
Media center
Events and webinars
Responsible Business
Alumni

Knowledge

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Follow us:

Resources

Supply Chains

Access our latest insights into supply chain risk management and governance.

Distressed Banks

Navigate the legal implications relating to banks in distress with our resource center.

Premium services

Click here to learn more about our range of premium tools

Comparative guides

View the global picture with our interactive comparative guides

Publications

Search

No results found

2

Filter by type

Insights and Analysis
News

Aerospace and Defense
Energy and Natural Resources
Financial Institutions
Insurance
Life Sciences and Health Care
Mobility and Transportation
Private Capital
Technology and Telecoms
Transportation and Logistics

Administrative and Public Law
Antitrust and Competition
Capital Markets
Copyright
Designs
Digital Assets and Blockchain
Domain Names
Energy Regulatory
Government Relations and Public Affairs
Health
Infrastructure, Energy, Resources, and Projects
Intellectual Property
International Trade and Investment
International Trade Commission Section 337
Investment Funds
IP and Technology Transactions
Joint Ventures
Medical Device and Technology Regulatory
Mergers and Acquisitions
Nuclear Energy and Materials
Patents
Pharmaceuticals and Biotechnology Regulatory
Privacy and Cybersecurity
Private Equity
Restructuring and Special Situations
Sovereigns
Space and Satellite
Strategic Operations, Agreements and Regulation
Trade Secrets and Confidential Know-how
Trademarks and Brands
Venture Capital and Emerging Companies

China Trade and Security
Environmental, Social, and Governance (ESG)
Eye on DC: Legislative and Regulatory Developments from the U.S. Capitol
Regulatory, Compliance & Investigation Solutions
Supply Chain Legal Issues
UK2030: defining a path to global business competitiveness

2024
2023
2022

Amsterdam
Beijing
Berlin
Boston
Brussels
Denver
Dubai
Dublin
Dusseldorf
Hamburg
Hong Kong
Houston
London
Los Angeles
Madrid
Milan
Minneapolis
Munich
New York
Northern Virginia
Paris
Philadelphia
Shanghai
Silicon Valley
Tokyo
Washington, D.C.

News

2024 Life Sciences & Health Care Horizons

18 April 2024

While economic factors, including the high cost of capital, continue to keep our clients up at night, we also see signs of optimism in 2024. Against this fiscal backdrop, significant recent ...

News

Commission investigation into termination of pipeline drug: what next for R&D decision-making?

02 April 2024

The European Commission has opened a formal investigation into whether Zoetis, a US animal health company, has acted in breach of the abuse of dominance rules by terminating development of...

Insights and Analysis

Unsung regulatory approval vital to deal closing in acquiring businesses using radioactive materials

29 March 2024

Advancements in medical technology make healthcare and radiopharmaceutical companies attractive investment prospects. And we are seeing this interest in real time. However, acquiring...

Insights and Analysis

Key considerations for life sciences demerger deals in China

28 March 2024

This article discusses the most important legal and regulatory considerations for life sciences companies considering a demerger in China. The authors address the challenges and issues...

News

Spotlight on the U.S.: Panelists discuss navigating the IRA

04 March 2024

Hogan Lovells is hosting a special webinar series for Life Sciences and Health Care companies based in, or with commercial interests in, the Asia-Pacific (APAC) region. The series shares...

News

Revealing the covert economics of licensing and collaborations: Technology transfers

29 February 2024

Although upfront fees, milestones and royalties often take the spotlight in deal announcements in the life sciences sector, there exist numerous other cost allocation principles within...

News

Advances in Precision Medicine, the Future of Diagnostics, and FDA Priorities in an Election year

21 February 2024

Speaking at the J.P. Morgan Healthcare Conference this year, Hogan Lovells life sciences regulatory partners Lowell Zeta and Blake Wilson, were joined by Greenleaf Health’s Kalah...

News

BIOSECURE Act aims to restrict funding and genetic data use by foreign adversary biotech companies

15 February 2024

The BIOSECURE Act (the “Act”), introduced by members of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party...

News

The European Commission report on competition enforcement in the pharmaceutical sector

01 February 2024

On 26 January 2024, the European Commission published a report on competition enforcement in the pharmaceutical sector, highlighting the role of EU competition law in safeguarding market...

Load more

Stay in the know Subscribe

Connect with us

Quick Links

Our people
Case studies
Our thinking

Responsible Business
Diversity, Equity & Inclusion

About us
Join us
Contact us

Cookies
Disclaimer
Legal notices
Modern Slavery Statement
Privacy
RSS

© 2024 Hogan Lovells. All rights reserved. "Hogan Lovells" or the “firm” refers to the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses, each of which is a separate legal entity. Attorney advertising. Prior results do not guarantee a similar outcome.